Treatment effects of DC101 and methotrexate (MTX) on RL lymphoma xenografts
Agent . | Dose . | Average tumor diameter, mm ± SE . | Average tumor volume (TV), mm3 ± SE . | P to TV IVIG vs treatment . |
|---|---|---|---|---|
| IVIG | 800 μg 2×/wk | 14.9 ± 0.5 | 1744 ± 493 | NA |
| MTX | 40 μg 2×/wk | 13.5 ± 0.6 | 1341 ± 145 | ≤ .07 |
| DC101 | 400 μg 3×/wk | 12.1 ± 0.5 | 972 ± 112 | ≤ .002 |
| MTX + DC | 400 μg 2×/wk and 400 μg 3×/wk | 9.7 ± 0.7 | 530 ± 113 | ≤ .0001 |
Agent . | Dose . | Average tumor diameter, mm ± SE . | Average tumor volume (TV), mm3 ± SE . | P to TV IVIG vs treatment . |
|---|---|---|---|---|
| IVIG | 800 μg 2×/wk | 14.9 ± 0.5 | 1744 ± 493 | NA |
| MTX | 40 μg 2×/wk | 13.5 ± 0.6 | 1341 ± 145 | ≤ .07 |
| DC101 | 400 μg 3×/wk | 12.1 ± 0.5 | 972 ± 112 | ≤ .002 |
| MTX + DC | 400 μg 2×/wk and 400 μg 3×/wk | 9.7 ± 0.7 | 530 ± 113 | ≤ .0001 |
NA indicates not applicable.